Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers

BMC Medicine

Angelo Di Leo²  Cristina Guarducci¹  Christopher D Hart²  Luca Malorni²  Ilenia Migliaccio¹ 

[1] Translational Research Unit, Hospital of Prato, Istituto Toscano Tumori, Via Suor Niccolina 20, Prato, 59100, Italy;“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Via Suor Niccolina 20, Prato, 59100, Italy

关键词: Metastatic breast cancer;    Hormone receptor positive breast cancer;    HER2 negative breast cancer;    Endocrine therapy;   

Others  :  1134624
DOI  :  10.1186/s12916-015-0280-0

 received in 2014-11-26, accepted in 2015-01-20,  发布年份 2015

【 摘 要 】

The standard of care for patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancer is endocrine therapy. Endocrine agents, including aromatase inhibitors, tamoxifen, and fulvestrant, are often administered alone as first line treatment and demonstrate durable responses with limited side effects. Endocrine resistance represents a major clinical problem. In the future, poly-endocrine therapy and combination therapies with biological agents might become valuable options for the first line treatment of hormone receptor-positive advanced breast cancer. However, it will be critical to develop clinical tools that can reliably identify the subgroup of patients most likely to benefit from endocrine therapy alone, and those who might benefit from alternative approaches.

Herein, we will review and discuss current issues in the endocrine treatment of postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancer.

【 授权许可】

   
2015 Migliaccio et al.; licensee BioMed Central.

【 参考文献 】

• [1]Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al.: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) dagger. Ann Oncol. 2014, 25:1871-88.
• [2]Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, et al.: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981, 304:16-21.
• [3]Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al.: Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009, 27:4530-5.
• [4]Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004, 22:1605-13.
• [5]Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001, 19:2596-606.
• [6]Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al.: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000, 18:3748-57.
• [7]Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncology. 2000, 18:3758-67.
• [8]Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al.: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008, 26:4883-90.
• [9]Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer. 2003, 39:1684-9.
• [10]Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003, 21:2101-9.
• [11]Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al.: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012, 136:503-11.
• [12]Robertson JFR, Llombart-Cussac A, Feltl D, Dewar J, Jasiówka M, Hewson N, et al. Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: overall survival from the phase II ‘first’ study. Presented at the 2014 San Antonio Breast Cancer Symposium; December 9–13, 2014; San Antonio, Texas. Abstract S6–04.
• [13]Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.: Molecular portraits of human breast tumours. Nature. 2000, 406:747-52.
• [14]Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003, 100:8418-23.
• [15]Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al.: Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014, 32:2794-803.
• [16]van de Vijver MJ: Molecular tests as prognostic factors in breast cancer. Virchows Arch. 2014, 464:283-91.
• [17]Di Leo A, Malorni L: Polyendocrine treatment in estrogen receptor-positive breast cancer: a “FACT” yet to be proven. J Clin Oncol. 2012, 30:1897-900.
• [18]Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattstrom D, et al.: FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012, 30:1919-25.
• [19]Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al.: Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012, 367:435-44.
• [20]Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, et al.: Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013, 14:989-98.
• [21]Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al.: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010, 28:4594-600.
• [22]Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al.: Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014, 106:djt337.
• [23]Osborne CK, Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011, 62:233-47.
• [24]Lauring J, Park BH, Wolff AC: The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 2013, 11:670-8.
• [25]Migliaccio I, Di Leo A, Malorni L: Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol. 2014, 26:568-75.
• [26]Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012, 366:520-9.
• [27]Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015, 16:25-35.
• [28]Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al.: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 2014, 25:2357-62.
• [29]Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJ, et al.: Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 2014, 32:2951-8.
• [30]Hortobagyi GNP-GMJ, Rugo HS, Burris HA, Campone M, Noguchi S, Perez AT, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2013;31(suppl:abstr LBA509).
• [31]Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, et al.: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010, 107:10208-13.
• [32]Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, et al.: PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One. 2013, 8:e53292.
• [33]Network CGA: Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490:61-70.
• [34]Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, et al.: Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol 2015, 26:120-5.
• [35]Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, et al.: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011, 10:1093-101.
• [36]Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, et al.: Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. Breast Cancer Res Treat. 2014, 147:211-9.
• [37]Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, et al.: PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011, 17:667-77.
• [38]Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015. [Ahead of print.]
• [39]Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, et al.: Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer. 2014, 14:456. BioMed Central Full Text
• [40]Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, et al.: Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014, 6:1371-86.
• [41]Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, et al.: PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin Cancer Res. 2014, 20:5823-34.
• [42]Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, et al.: Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010, 120:461-7.
• [43]Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, et al.: Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014, 20:2643-50.
• [44]Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, et al.: Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014, 25:1959-65.
• [45]Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, et al.: Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2010, 119:379-90.
• [46]Mayer IA, Arteaga CL: PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer? J Clin Oncol 2014, 32:2932-4.
• [47]Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al.: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010, 120:2406-13.
• [48]Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al.: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012, 30:2718-24.
• [49]Ciruelos Gil EM: Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014, 40:862-71.
• [50]Krop IJS, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results. Presented at the 2014 San Antonio Breast Cancer Symposium; December 9–13, 2014; San Antonio, Texas. Abstract: S2–02.
• [51]Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al.: Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013, 31:2128-35.
• [52]Jerusalem G, Bachelot T, Barrios C, Neven P, Di Leo A, Janni W, et al.: A new era of improving progression-free survival with dual blockade in postmenopausal HR, HER2 advanced breast cancer. Cancer Treat Rev 2015, 41:94-104.